Non-Hodgkin Lymphoma (NHL) is a relatively common type of cancer that develops in either B lymphocytes or T lymphocytes (B cells and T cells), with B cells making up 85% of the total lymphocytes and T cells making up 15%.
NHL is the 10th most common cancer and accounts for 4.3% of all cancer cases in the US.
There are an estimated 850,000 prevalent patients with B-cell NHL. Approximately 150,000 patients who are not in remission require active treatment (US, top 5 EU).
66% of diagnosed patients age 55-74 years.
NHL is characterized by repeated remissions and relapses, and it has a high mortality rate, despite available treatments:
- 3.2% of all cancer deaths in the US
- 5-yr survival rate: 69.3% (US, 2004-2010)
Current treatments for NHL are based around CD20-targeted immunotherapies (dominated by rituximab) and chemotherapies, but for relapsing patients there is a high unmet need for novel therapies.
Sources: DataMonitor Pipeline Insight: Lymphomas, Multiple Myeloma and Myelodysplastic Syndromes DMHC2595/ Published 03/2010, National Cancer Institute at the National Institutes of Health, seer.cancer.gov/, annonc.oxfordjournals.org/content/19/3/570.full